Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE

This study is testing whether a drug called dasatinib can help people with acute myeloid leukemia (AML) — a fast-moving blood cancer — whose disease stopped responding to a common two-drug treatment combination (venetoclax plus azacitidine). **You may be eligible if...** - You have a confirmed diagnosis of AML (except for certain subtypes: Philadelphia chromosome-positive AML or AML M3) - Your AML did not respond to at least two cycles of the venetoclax plus azacitidine combination - You are 18 years or older with an ECOG score of 3 or less - You have signed an informed consent form **You may NOT be eligible if...** - You are eligible for another targeted therapy with market authorization - You have heart failure, liver failure, or kidney failure - You have HIV with detectable viral load, or active hepatitis B or C - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.